XGN vs. BNR, PSNL, ENZ, RNLX, PMD, DMTK, BGLC, OPGN, FRES, and ACON
Should you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Burning Rock Biotech (BNR), Personalis (PSNL), Enzo Biochem (ENZ), Renalytix (RNLX), Psychemedics (PMD), DermTech (DMTK), BioNexus Gene Lab (BGLC), OpGen (OPGN), Fresh2 Group (FRES), and Aclarion (ACON). These companies are all part of the "medical laboratories" industry.
Exagen (NASDAQ:XGN) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.
Exagen has higher earnings, but lower revenue than Burning Rock Biotech. Exagen is trading at a lower price-to-earnings ratio than Burning Rock Biotech, indicating that it is currently the more affordable of the two stocks.
Exagen has a net margin of -34.74% compared to Burning Rock Biotech's net margin of -113.39%. Burning Rock Biotech's return on equity of -71.22% beat Exagen's return on equity.
Exagen received 15 more outperform votes than Burning Rock Biotech when rated by MarketBeat users. Likewise, 54.05% of users gave Exagen an outperform vote while only 31.25% of users gave Burning Rock Biotech an outperform vote.
In the previous week, Burning Rock Biotech had 8 more articles in the media than Exagen. MarketBeat recorded 10 mentions for Burning Rock Biotech and 2 mentions for Exagen. Exagen's average media sentiment score of 0.92 beat Burning Rock Biotech's score of 0.40 indicating that Exagen is being referred to more favorably in the media.
Exagen currently has a consensus target price of $7.00, suggesting a potential upside of 258.97%. Given Exagen's higher possible upside, analysts plainly believe Exagen is more favorable than Burning Rock Biotech.
75.3% of Exagen shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 26.1% of Exagen shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Exagen has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.
Summary
Exagen beats Burning Rock Biotech on 11 of the 17 factors compared between the two stocks.
Get Exagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
